New combo therapy aims to shrink head and neck tumors

NCT ID NCT06959082

Recruiting now Disease control Sponsor: VSPharmTech Co.,Ltd. Source: ClinicalTrials.gov ↗

First seen Feb 27, 2026 · Last updated May 04, 2026 · Updated 11 times

Summary

This study tests whether adding an experimental drug called VS-101 to standard chemoradiotherapy helps control head and neck cancer better than standard treatment alone. About 30 adults with squamous cell carcinoma of the mouth, throat, or voice box will take part. The main goal is to see if the cancer shrinks or stays stable at 6 and 12 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Cancer Center of Kansas
RECRUITING

Wichita, Kansas, 67214, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
NYU Langone Health
RECRUITING

Manhattan, New York, 10016, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Yale Cancer Center
RECRUITING

New Haven, Connecticut, 06510, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HEAD AND NECK CANCER SQUAMOUS CELL CARCINOMA HEAD AND NECK CANCER SQUAMOUS CELL CARCINOMA